Gemcitabine
Active pharmaceutical substance formulated in Jan Aushadhi generic products for Oncology & Critical Care treatment.
🧴 Clinical Application
Administer intravenously only over 30 minutes diluted in 0.9% NaCl. Infusion time must NOT exceed 60 minutes or be given more frequently than once weekly, as prolonged infusions increase the formation of toxic intracellular metabolites and dramatically escalate myelosuppressive and pulmonary toxicity.
⚠️ Side Effects
Common: Bone marrow suppression (neutropenia, thrombocytopenia), flu-like syndrome (fever, chills, myalgia within 6-12 hours of infusion), transient proteinuria/hematuria, transaminase elevations, nausea. Rare/Severe: Hemolytic Uremic Syndrome (HUS) / Thrombotic Microangiopathy (TMA), acute respiratory distress syndrome (ARDS), and capillary leak syndrome.
🛡️ Safety Warnings
Black Box Warning: Prolonging infusion time beyond 60 minutes or dosing more often than once weekly increases severe toxicity. Monitor CBC with differential prior to each dose. Discontinue immediately if signs of microangiopathic hemolytic anemia or respiratory distress occur.
Jan Aushadhi Products containing Gemcitabine
Found 2 generic formulation(s) containing this active ingredient.
Gemcitabine Injection 1000mg
Gemcitabine Injection (200mg, 1000mg) is a difluoronucleoside pyrimidine antimetabolite on the WHO Model List of Essential Medicines. It is intracellularly phosphorylated to gemcitabine diphosphate (which inhibits ribonucleotide reductase, depleting deoxynucleotide pools) and gemcitabine triphosphate (which incorporates into replicating DNA, adding one additional nucleotide before DNA polymerases stall completely, masked from proofreading repair enzymes). Indicated for advanced pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), metastatic breast cancer, and advanced ovarian and bladder carcinomas.
Gemcitabine Injection 200mg
Gemcitabine Injection (200mg, 1000mg) is a difluoronucleoside pyrimidine antimetabolite on the WHO Model List of Essential Medicines. It is intracellularly phosphorylated to gemcitabine diphosphate (which inhibits ribonucleotide reductase, depleting deoxynucleotide pools) and gemcitabine triphosphate (which incorporates into replicating DNA, adding one additional nucleotide before DNA polymerases stall completely, masked from proofreading repair enzymes). Indicated for advanced pancreatic adenocarcinoma, non-small cell lung cancer (NSCLC), metastatic breast cancer, and advanced ovarian and bladder carcinomas.
Brand Equivalents & Price Comparison
Compare Jan Aushadhi generic prices against popular commercial brands for Gemcitabine.
| Generic Formulation | Pack Size | Jan Aushadhi Price | Commercial Brand Equivalents | Avg. Commercial Price | Savings |
|---|---|---|---|---|---|
| Gemcitabine Injection 1000mg | Vial | ₹783.75 | GEMWEM, CITAFINE | ₹5206.60 | 85% Save |
| Gemcitabine Injection 200mg | Vial | ₹225.00 | GEMCIGLAN, GEMWEM, GEMKERB, GEM | ₹1411.19 | 84% Save |
Frequently Asked Questions (FAQ)
Get answers to common queries about Gemcitabine generics.